MCH antagonists and their use in the treatment of obesity

US6472394B1 · kind B1 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Brian McKittrick · New Vernon, US
• Jing Su · Scotch Plains, US
• John W. Clader · Cranford, US
• Shengjian Li · Montgomery, US
• Guihau Guo · Plainsboro, US

Key dates

• Filing date: Dec 17, 2001
• Grant date: Oct 29, 2002
• Expiry date: Dec 17, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds represented by structural formula I: or a pharmaceutically acceptable salt, ester or solvate thereof, whereinW is R1—CR3R12NR4C(O)— or R11C(O)NR4—;the dotted line is an optional double bond;X is —CHR8—, —C(O)—, or —C(═NOR9)—;Y is R1 is optionally substituted cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkyl-alkyl;R2 is optionally substituted aryl or heteroaryl;R3 is alkyl, aryl or heteroaryl;R4 and R12 are H or alkyl;R8 is H, alkyl or alkoxyalkyl;R9 is H, alkyl or arylalkyl;R10 is H, alkyl or aryl;R11 is or, when R2 is R6-heteroaryl or R10 is not H, R11 can also be R5-phenylalkyl;n is 1-3 and m is 1-5; andR14 is 1-3 substituents selected from H, alkyl, halogen, —OH, alkoxy and CF3;and pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of eating disorders and diabetes.